# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Andrew Fein maintains Catalyst Pharmaceuticals (NASDAQ:CPRX) with a Buy and raises the price...
Citigroup analyst Samantha Semenkow maintains Catalyst Pharmaceuticals (NASDAQ:CPRX) with a Buy and raises the price target ...
Truist Securities analyst Joon Lee maintains Catalyst Pharmaceuticals (NASDAQ:CPRX) with a Buy and raises the price target f...
Catalyst Pharmaceuticals (NASDAQ:CPRX) reported quarterly earnings of $0.56 per share which beat the analyst consensus estimate...